BYSI BeyondSpring Inc.
Price Chart
Executive Summary
BeyondSpring announced a leadership transition effective July 1, 2026: founder/CEO Dr. Lan Huang steps down as CEO (remains Chairman) to focus on SEED Therapeutics; Min Qiu appointed CEO and Na Li appointed CFO, both with a mandate to execute the confirmatory DUBLIN-4 Phase 3 trial for Plinabulin. The filing includes no financial data, guidance, or material operational updates — it is a governance restructuring with no quantifiable impact on fundamentals.
Actionable Insight
This is a governance restructuring with no financial data — neutral for the stock. Monitor DUBLIN-4 enrollment updates and the upcoming 8-K amendment for CEO/CFO compensation terms. The forfeiture of Huang's unvested equity removes a potential overhang but is not a catalyst.
Key Facts
- Founder/CEO Dr. Lan Huang transitions from CEO to Chairman effective July 1, 2026; all her unvested equity and long-term incentive awards forfeited.
- Min Qiu appointed CEO effective July 1, 2026; employment terms not yet finalized.
- Na Li appointed CFO effective July 1, 2026; employment terms not yet finalized.
- Dr. Jiangwen Majeti appointed Vice Chairman of the Board; receives one-time grant of options to purchase 100,000 shares vesting over 4 years.
- DUBLIN-4 is a 442-patient confirmatory Phase 3 trial of Plinabulin plus docetaxel in non-squamous EGFR wild-type NSCLC post-ICI.
- No financial results, guidance, or preliminary data disclosed in this filing.
Financial Impact
No financial figures disclosed. Leadership transition is a governance event with no immediate revenue, earnings, or cash flow impact.
Risk Factors
- CEO/CFO compensation terms not yet disclosed — could include dilutive equity grants.
- DUBLIN-4 execution risk remains the primary binary catalyst; no update on enrollment or timeline in this filing.
- Founder CEO departure may signal reduced strategic focus on BeyondSpring vs. SEED Therapeutics.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003908 |
| Document: f8k_060426.htm | 0001171843-26-003908 |
| Document: 0001171843-26-003908-index-headers.html | 0001171843-26-003908 |
| Document: 0001171843-26-003908-index.html | 0001171843-26-003908 |
| Document: 0001171843-26-003908.txt | 0001171843-26-003908 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
8d ago
|
8-K
| $1.71 $1.71 | · 0.00% | ▲ +2.60% | $1.57 (−8.19%) |
|
Jun 2, 2026
10d ago
|
Press Release
| $1.70 $1.74 | ▲ +2.35% | ▲ +3.07% | $1.57 (−7.65%) |
|
May 13, 2026
4w ago
|
8-K
| $1.45 $1.47 | ▲ +1.38% | ▲ +0.60% | $1.57 (+8.28%) |
|
May 13, 2026
4w ago
|
Press Release
| $1.45 $1.47 | ▲ +1.38% | ▲ +0.60% | $1.57 (+8.28%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $1.61 $1.60 | ▼ −0.62% | ▲ +1.06% | $1.57 (−2.48%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $1.68 $1.61 | ▼ −4.17% | ▼ −2.40% | $1.57 (−6.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access